Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

The group differences appeared greater when assessing baseline tumour volumes than when calculating dynamic % changes in tumour volumes between baseline and end of cycle 2 (weakly significant p < 0.047).

also in 211 other papers

Predicting End of Treatment Response by T1CE Percentage Volume Change (Baseline to 2 MATRix Cycles) There was a borderline significant difference in change in absolute tumour volume from baseline to the completion of two treatment cycles between Group 1 and Group 2, with a smaller reduction in T1CE volume in non-responders ( p < 0.047).

also in 1,379 other papers